Aspire Bizarma在CPHI法兰克福展示舌下高剂量阿司匹林

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the CPHI Frankfurt trade show, the world's largest pharmaceutical event. The Company engaged in numerous strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities for its lead product candidate, a novel sublingual high-dose aspirin.

Held in Frankfurt, Germany, from October 27-30, CPHI unites professionals across the entire pharma supply chain to collaborate, build relationships, and drive business forward. This year's event hosted over 63,000 attendees from 160 countries and featured 2,400 exhibitors. During the conference, Aspire's management team conducted 16 formal, face-to-face meetings and dozens of informal conversations with interested parties. Notable discussions were held with representatives from major industry players including Deva Holdings, Abiogan, Bayer, Key Pharmaceuticals, AI Branding, TGC Health, Instapill, and Zerion, among others.

Steve Quesenberry, who serves as counsel for Aspire and represented the Company at the event, stated, "Attending CPHI Frankfurt was an invaluable experience for Aspire. The sheer scale of the event is impressive, but the real value was in the quality of our interactions. Having sixteen face-to-face meetings, in addition to many other promising conversations, allowed us to directly showcase the compelling clinical data for our sublingual high-dose aspirin. The reception was overwhelmingly positive, and these discussions with major industry players are a critical step toward establishing the strategic partnerships needed to bring our innovative product to a global market."

The primary focus of these discussions was Aspire's sublingual high-dose aspirin, which recently reported positive final results from its investigational study. The study demonstrated that Aspire's formulation produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA), the active antiplatelet form of aspirin, compared to chewed aspirin tablets. This is critically important for its potential use in treating suspected acute myocardial infarction (AMI), or heart attack.